Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Growth Metrics

Bioadaptives (BDPT) Asset Writedowns and Impairment (2024)

Bioadaptives' Asset Writedowns and Impairment history spans 1 years, with the latest figure at $60000.0 for Q3 2024.

On a quarterly basis, Asset Writedowns and Impairment changed N/A to $60000.0 in Q3 2024 year-over-year; TTM through Sep 2025 was $60000.0, a N/A change, with the full-year FY2024 number at $18000.0, changed N/A from a year prior.
Asset Writedowns and Impairment hit $60000.0 in Q3 2024 for Bioadaptives.
Over the last five years, Asset Writedowns and Impairment for BDPT hit a ceiling of $60000.0 in Q3 2024 and a floor of $60000.0 in Q3 2024.